A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
This study is testing a medication called selinexor to see if it can help children and young people with certain hard-to-treat solid tumors, including Wilms tumor and other rare cancers. Researchers want to see if this targeted drug can help stop cancer cells from growing when other treatments haven't worked.
This study is open to patients starting from toddlers up to adults who have specific types of recurrent or hard-to-treat solid tumors. Participants must be able to follow study rules and provide consent or have a parent/guardian provide it.
Participants will receive the study medication, selinexor, which is designed to block specific proteins inside cancer cells. Doctors will monitor health and safety closely through regular check-ups during the treatment process.
The study is currently recruiting patients at medical centers in Los Angeles, Palo Alto, and Washington D.C. It is an active Phase II trial.
- 1Testing a targeted cancer medicine called selinexor
- 2For children and young patients with specific hard-to-treat solid tumors
- 3Currently recruiting at multiple medical centers in the United States
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.